Prosthetic Joint Infection, Staphylococcus
Conditions
Brief summary
The alternatives to the combination of Fluoroquinolone and Rifampicin in prosthetic joint infections (PJI) caused by staphylococcus are currently unclear. Clindamycin is prescribed as dual therapy in this indication, and provides many advantages. We conducted a multicenter retrospective observational study evaluating the efficacy and safety of Clindamycin in prosthetic joint infections due to staphylococcus between January 2013 and December 2019.
Interventions
None listed
Sponsors
University Hospital, Brest
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients with PJI defined according to the IDSA. * Infection must be mono-microbial or multi-microbial with Staphylococcus spp sensitive to Clindamycin. * Infection may be acute or chronic, nosocomial or community-acquired. * Patient having received a curative treatment with Clindamycin.
Exclusion criteria
* Patients with osteitis, osteomyelitis, septic arthritis in native joints, diabetic foot infections, spondylodiscitis, infections in external fixator, surgical site infections following neurosurgical management, bedsores, skin and soft tissue infections. * Patients with mono-microbial infections other than Staphylococcus, multi-microbial infections including other bacteria than Staphylococcus, suspected Osteoarticular Infection without microbial identification. * Patients with clindamycin-resistant Staphylococcal PJI, constitutive MLSb phenotype. * Patients having received suspensive treatment with Clindamycin. * Patients treated with Clindamycin as last line of treatment for a duration of less than 14 days. * Patients refusing to participate * Patients under legal protection (guardianship, curatorship, ..)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Failure of Clindamycine | within 2 years of the diagnosis (within one year for patients diagnosed in December 2019) | New diagnosis of PJI at the same site, caused by the same microbial agent |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety of Clindamycin | During the treatment and 6 month after | Safety of Clindamycin in the treatment of PJI |
| Correlation between failure of Clindamycin and blood level of Clindamycin | within 2 years of the diagnosis (within one year for patients diagnosed in December 2019) | — |
Countries
France
Outcome results
None listed